VolitionRx Completes $2 Million Funding Round With Significant Investor Partnership

VolitionRx Secures $2 Million in Funding

On January 8, 2026, VolitionRx Limited, trading on the NYSE AMERICAN under the symbol VNRX, announced a significant achievement in its funding operations. The multi-national epigenetics company has entered into an updated securities purchase agreement with Lind Global Asset Management XII LLC, a notable institutional investment fund based in New York. This collaboration is expected to fortify Volition's position in the market, promoting further advancements in the field of epigenetics.

Details of the Funding

Under the amended agreement, VolitionRx will receive gross proceeds amounting to $2 million. This funding is part of a larger financial structure that includes the issuance of a senior secured convertible promissory note valued at approximately $2.4 million, which is referred to as the 2026 Note. Additionally, the agreement grants a five-year warrant allowing the acquisition of up to 7,000,350 shares of Volition’s common stock at a specified exercise price of $0.5714 per share. To cement this deal, the company will also pay a commitment fee of $70,000, deducted directly from the impending funds.

This latest agreement is an extension of a prior arrangement made in May 2025, in which VolitionRx had already established a securities purchase agreement for a senior secured convertible promissory note amounting to $7.5 million. The initial deal involved numerous shares of common stock warrants and was a significant step forward for Volition in securing the necessary capital for its developmental initiatives.

Repayment and Conversion Terms

The 2026 Note, which does not accrue interest, is structured to be repaid in 18 monthly installments starting six months post-issuance. Each installment will be approximately $133,333, with provisions allowing the investor to adjust payment amounts under certain conditions. Notably, VolitionRx is permitted to fulfill these payments through cash, issuance of common stock, or a combination of both, thereby providing the company with flexibility in financial management.

In addition to the note, the outstanding principal can be converted into shares of common stock at the aforementioned price of $0.5714 each, offering an enticing option for investors looking to increase their stake in the company.

Future Innovations and Research Focus

VolitionRx is dedicated to enhancing the field of epigenetics and aims to deliver breakthroughs in disease detection and monitoring. The company focuses on the development of cost-effective blood tests that can aid in the early detection of various diseases, including specific types of cancer and conditions tied to NETosis, such as sepsis. Through its operations in Belgium and the UK, as well as an innovation lab in the United States, VolitionRx actively strives to improve patient outcomes and quality of life through its innovative approaches.

“Early detection is crucial in saving lives,” said a representative from VolitionRx. The company’s commitment towards advancing technology in the medical sector showcases the potential impacts better diagnostic tools could have not just on longevity, but also on enhancing the overall patient experience.

Requirements Following Funding

According to stipulations set forth in the amended agreement, VolitionRx will be required to file a registration statement within 30 days following the closure of this funding to facilitate the potential resale of shares linked to the 2026 convertible note and the warrants. This is a standard regulatory requirement aimed at ensuring investor transparency and compliance with securities laws.

Conclusion

In summary, VolitionRx's recent funding round represents a significant milestone in its ongoing mission to advance the science of epigenetics. The impressive backing from Lind Global Asset Management signifies investor confidence in Volition’s potential for innovation and success. With these new funds secure, the company is poised to continue its critical work in the biomedical field, ultimately striving to enhance lives with groundbreaking diagnostic advancements.

For further inquiries or to stay updated on Volition's progress, investors and interested parties can reach out via their media and investor relations contacts.